- The results of Amarin’s (NASDAQ:AMRN) pivotal ANCHOR Phase 3 clinical trial are now available electronically through The American Journal of Cardiology and are scheduled for … Continue Reading
Read now- Zogenix (NASDAQ:ZGNX) has officially priced its announced stock offering at $2.00/unit, each unit consisting of one share of common stock and one warrant to purchase … Continue Reading
Read now- The laboratory analytical products company (NYSE:WAT) reported second quarter adjusted EPS of $1.17, above Wall Street’s Consensus estimate of $1.16. However, WAT missed revenue estimates, … Continue Reading
Read now- Elan Corp. (NYSE: ELN) and its development partners, Pfizer (NYSE: PFE) and Johnson and Johnson (NYSE:JNJ), announced that their Alzheimer’s treatment candidate, bapineuzumab, did not … Continue Reading
Read nowLong Ideas - Novartis AG (NYSE:NVS) announced this morning that its generics division, Sandoz, has completed takeover of private dermatology provider Fougera Pharmaceuticals in a $1.5B deal. Although … Continue Reading
Read now- Synergy Pharmaceuticals (NASDAQ: SGYP) announced Friday that it plans to merge with Callisto Pharmaceuticals (NASDAQ: CLSP), which happens to be Synergy’s largest shareholder. SGYP is … Continue Reading
Read now- Pluristem (NASDAQ:PSTI) continues its upward trend this morning on news Wednesday that the company is partnering with CPC Clinical Research to begin a Phase II … Continue Reading
Read now